Pulmonx is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of lung disorders.
Currently, our products focus on the treatment of the over expansion (hyperinflation) of the lungs which is caused by emphysema. The goal is to reduce the hyperinflation that makes people with emphysema feel out of breath and restricts their activities and quality of life. Reducing lung volume can make patients feel better, breathe easier, and potentially even help them resume some of their normal life activities.1,2,3
Our Patient Information Guide
(English) provides information for you to discuss with your doctor about how Pulmonx products can help people with emphysema.
At this time, treatment with Pulmonx products is not available in the U.S. If you live in a country outside the U.S. and are interested in learning more, please click here to find out where treatment with Pulmonx products is available.
- Sciurba F, et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. New England Journal of Medicine, 2010; 363:1233-1244.
- Gompelmann D, Eberhardt R, Ernst A, et al. Predicting Atelectasis Using Collateral Ventilation Assessment prior to Endobronchial Lung Volume Reduction – A Feasibility Study. Respiration 2010;80:419-425; doi: 10.1159/000319441.
- Use of Chartis® Pulmonary Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR). Chartis Multi-Centre Study, data presented at ATS2011. Data on file with Pulmonx.
